Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GroSciences was a Colorado subsidiary of Digipath focused on cannabis and hemp product development, cultivar identification, and related canna-tech offerings. The business was launched to leverage Digipath's cannabis testing data and scientific capabilities to support formulation development, quality improvement, and human wellness-oriented cannabis products. Publicly disclosed products and programs included the Tru-Hemp ID DNA-based assay kit for cultivar identification and TERPO+ Broadspectrum, a plant-derived pesticide and decontamination product for cannabis and hemp cultivation. Based on available public information, GroSciences appears to have operated as a small, non-public business unit within Digipath rather than as a standalone drug-development biotech with a traditional therapeutic pipeline. It does not appear to be an active clinical-stage life sciences company as of April 5, 2026.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GroSciences.